Wegovy weight-loss drug maker targets European governments

Analysts estimate the obesity market could be worth as much as $100bn (€92bn) by the end of the decade as the race to develop weight-loss drugs heats up

Wegovy weight loss drug: Novo Nordisk CEO speaks about its plans for Europe. 

Novo Nordisk aims to convince Europeans governments to pay for its obesity drug Wegovy for the most overweight or those with co-morbidities, its chief executive has said, emphasising both the medical and cost benefits of the treatment.

Lars Fruergaard Jorgensen's comments were the most detailed yet on the drugmaker's strategy for expanding in Europe.